 |  |  |
|
 |
 |
|||
 |
 |
 |
|
|||||
|
 |
|
Proprietary Gel Matrix Adhesive Balancing Adhesion Reliability and Gentleness At the forefront of innovation, Aveva and Nitto Denko produced the first and only marketed transdermal patch using a revolutionary Gel Matrix adhesive system for an unequaled balance of adhesion reliability and gentleness. Because the Gel Matrix adhesive doesn't cause a disruption of the stratum corneum (skin) during removal, these patches can be removed and reapplied with minimal skin irritation and a desirable patient experience is achieved. Early in the history of transdermal drug delivery systems, patch design included a chemically resistant backing that prevented the loss of drug and the permeation of liquids, a reservoir to store an adequate supply of active ingredient for continuous therapy, and an adhesive to attach the system to the patient's skin. As effective as these early models were, compliance remained low due to adhesion problems caused by the rigidity and high occlusive properties of the backings, the size required for the reservoir design and the skin irritation that resulted from the adhesive. |
|
|
|
|
||||
|
|||||
|